Please assess the completion status of the following clinical trial:

Trial Title: A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of rheumatoid arthritis~* Patients must be either DMARD naive or have failed at least one DMARD agent (e.g. MTX, leflunamide or sulfasalazine)~* Patients are allowed up to 3 DMARDs at study entry (e.g. MTX, sulfasalazine or hydroxychloroquine) as long as their dose was stable for 4 weeks prior to initiating study treatment~* Disease activity at screening defined by ≥6 out of 28 tender joints and ≥6 out of 28 swollen joints and hsCRP \>10mg/L~Exclusion Criteria:~* Patients with severe rheumatoid arthritis (functional status class IV according to the ACR 1991 revised criteria)~* Previous exposure to secukinumab or any other biologic, including TNF inhibitors.~* Use of high potency opioid analgesics~* Pregnant or nursing (lactating) women~* Use of any investigational drug other than RA therapy and/or devices at the time of randomization or within 30 days or 5 half-lives of randomization, whichever is longer.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab (Type: EXPERIMENTAL): 10 mg/kg intravenous (I.V.)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo I.V.

Based on this trial design, predict the completion outcome and termination type (if applicable).